A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Study Status
Open to Enrollment
Study Description
The purpose of this study is to determine whether therapy with pazopanib is effective and safe in women with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has not progressed on first line chemotherapy (standard therapy).
Disease Status and/or Stage
Ovary, Primary Peritoneal or Fallopian Tube Cancer
Sponsor
GlaxoSmithKline
Key Eligibility
- Women age 18 and older
- Confirmed stage II-IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- Cancer has been treated with surgical debulking and at least 5 cycles of platinum-taxane chemotherapy
- Study randomization at least 3 weeks, and not more than 12 weeks, from the date of the last chemotherapy dose
- All magor toxicities from the previous chemotherapy must have resolved
- Additional eligibility criteria discussed when you contact the study team
Principal Investigator
Contact
- Cynthia Delancy, RN
- (212) 746-3179
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
